3,6-dichloro-5-methyl-1,2,4-triazine | 132434-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 3,6-dichloro-5-methyl-1,2,4-triazine
• CAS: 132434-82-3
• 化学式: C₄H₃Cl₂N₃
• mdl: MFCD18250145
• 分子量: 163.994
• InChiKey: BHFPRKFRNIWENF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride 、 3,6-dichloro-5-methyl-1,2,4-triazine 在 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以58.3%的产率得到(3S,4S)-8-(6-chloro-5-methyl-1,2,4-triazin-3-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  参考文献：
  名称：

  WO2020201991A5

  摘要：

  公开号：

  WO2020201991A5
• 作为产物：
  描述：

  3,5,6-三氯-[1,2,4]-噻嗪 、 甲基溴化镁 以 四氢呋喃 为溶剂， 以46 %的产率得到3,6-dichloro-5-methyl-1,2,4-triazine
  参考文献：
  名称：

  WO2023/28536

  摘要：

  公开号：

文献信息

• [EN] TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER.<br/>[FR] DÉRIVÉS DE TRIAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2022253936A1

  公开（公告）日：2022-12-08

  The invention relates to novel compounds having the general formula Ib wherein R1, R2, R3, R4, R5and Z are as described herein, composition including the compounds and methods of using the compounds.

  该发明涉及具有一般式Ib的新化合物，其中R1、R2、R3、R4、R5和Z如本文所述，包括该化合物的组合物和使用该化合物的方法。
• SANEMITSU, YUZURU;NAKAYAMA, YOSHINORI;TANABE, YOO;MATSUMOTO, HIROSHI;HASH+, AGR. AND BIOL. CHEM., 54,(1990) N2, C. 3367-3369
  作者：SANEMITSU, YUZURU、NAKAYAMA, YOSHINORI、TANABE, YOO、MATSUMOTO, HIROSHI、HASH+

  DOI：——

  日期：——
• PROTEIN TYROSINE PHOSPHATASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP3947367A1

  公开（公告）日：2022-02-09
• SMALL MOLECULES FOR INHIBITING MALE FERTILITY
  申请人：The University of North Carolina at Chapel Hill

  公开号：US20170057934A1

  公开（公告）日：2017-03-02

  Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.
• sGC STIMULATORS
  申请人：IRONWOOD PHARMACEUTICALS, INC.

  公开号：US20170298055A1

  公开（公告）日：2017-10-19

  The present patent application discloses at least the compounds according to Formula Ia and Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, J B , n, J, R C1 , R C2 , Z 1 , Z 2 , W, X, Y 1 , Y 2 , J F and R 9 are as defined herein.